The TMHT (Thy1 Mutated Human Tau) mouse was developed in-house and is exclusively available at QPS Neuropharmacology. These animals represent a suitable model not only for Alzheimer’s disease but also for other tauopathies such as Frontotemporal Dementia and Parkinsonism linked to chromosome 17 (FTDP-17).
Various compounds of different classes were positively tested for their efficacy in the TMHT model. Published examples are the γ-secretase modulator CHF5074 (Lanzilotta 2010), sodium selenate (Corcoran et al., 2010) and grape-seed polyphenol extract (Wang et al., 2010).
TMHT mice express the longest human tau isoform Tau441 (2N4R) with two mutations, V337M and R406W, under regulatory control of the neuron-specific murine Thy1 promoter. Mice are bred on a C57BL/6 background. The human tau overexpression leads to high levels of soluble and sarcosyl insoluble tau in the brain that progressively increase. Furthermore, animal develop learning ad memory deficits.
TMHT mice are cryo-preserved and will be recovered upon request.
Figure 1: Phosphorylated tau at Thr231 in the hippocampus of 3-13 months old TMHT mice. Mean + SEM; n = 10. Two-way ANOVA with Bonferroni`s post hoc test. ***p<0.001.
Figure 2: Morris water maze test of 5 months old TMHT mice. Escape latency (A) and abidance in the target quadrant (B). Mean ± SEM, n = 7. A: Two-way ANOVA with Bonferroni`s post hoc test. B: Unpaired t-test.